What FDA's Latest mRNA Approvals Tell Us About CMC Expectations

FDA guidance documents tell you what the agency thinks it wants. Chemistry Review decisions tell you what the agency actually requires in practice. The gap between those two sources of truth is where IND submissions get into trouble — and where teams that read Chemistry Reviews carefully gain a real edge.

Why Chemistry Review Decisions Matter More Than Guidance Docs

FDA guidance is drafted by policy teams and often lags the scientific frontier. Chemistry Reviews are written by the same reviewers who will read your IND — they reflect current expectations, evolving analytical standards, and the specific questions reviewers are asking of new modalities. For mRNA/LNP therapeutics specifically, where the guidance landscape is still developing, Chemistry Reviews from recent approvals are the most accurate signal available for what your CMC package needs to contain.

Two mRNA/LNP approvals in Q1 2026 — both in the infectious disease space, one respiratory and one emerging pathogen — contained Chemistry Review sections that were notably more detailed than comparable reviews from 2023. The specificity increase reflects both reviewer experience with the modality and escalating expectations as the field matures.

Key Patterns from Q1 2026 mRNA/LNP Approvals

More Granular LNP Characterization Required

Both Q1 2026 Chemistry Reviews flagged LNP characterization packages that would have been considered adequate in 2023 as insufficient. Reviewers are now expecting characterization data that goes beyond batch-level summary statistics. Specifically, they want to see: component identity and purity for all four lipid components, lipid molar ratios with justification for the chosen formulation, and evidence of consistency across manufacturing scale transitions. The era of presenting a single representative formulation profile is over.

Specific Analytical Methods Now Expected

Reviewers in both approvals specifically called out analytical method expectations that go beyond what is stated in existing guidance. Three methods were referenced with enough specificity to be treated as de facto requirements for new IND submissions:

• Particle size distribution: dynamic light scattering (DLS) alone is no longer sufficient for IND-stage submissions. At least one orthogonal method — nanoparticle tracking analysis (NTA) or cryo-TEM — is expected alongside DLS, with data from multiple lots.
• Encapsulation efficiency: the Ribogreen assay remains acceptable, but reviewers expect the method to be fully validated with demonstrated selectivity, and the acceptance criterion must be justified based on biological activity data rather than arbitrary thresholds.
• Purity profiles: both reviews flagged submissions that presented total purity without adequately characterizing impurity identity. Truncated RNA species, double-stranded RNA (dsRNA) content, and residual process-related impurities each require dedicated analytical methods with specification justification.

What's Changed Since 2023 Approvals

The 2023 mRNA/LNP approvals — primarily COVID-19 vaccine updates — were reviewed with a degree of regulatory flexibility that reflected pandemic urgency. That flexibility has receded. Reviewers are now applying the analytical rigor appropriate to a maturing modality where multiple products are in development and comparative reviewer experience is substantial. Three specific shifts stand out:

• Stability specification tightening: 2023 approvals accepted stability specifications derived from small datasets. Q1 2026 reviews expect stability acceptance criteria to be derived from statistical analysis of at least three manufacturing lots.
• Process controls scrutiny: in-process controls, particularly for transcription yield and capping efficiency, now receive the same level of scrutiny as release specifications. Reviewers are checking that IPC specifications are grounded in manufacturing experience and not set arbitrarily.
• Container closure integrity: both Q1 2026 reviews referenced container closure integrity testing (CCIT) requirements in detail, indicating that probabilistic methods (visual inspection alone) are insufficient for vial presentations.

Three Changes to Make to Your 2026 IND CMC Package

1. Upgrade Your Particle Sizing Analytical Package

Add NTA or cryo-TEM as an orthogonal particle sizing method. Present data from a minimum of three lots at the scale you intend to use for IND-enabling studies. Include polydispersity data and explain how your size distribution is consistent with the biological activity data in your pharmacology section.

2. Stratify Your Purity Profile

Move from total purity to stratified purity: full-length capped mRNA content, dsRNA content (AGE or J2 antibody assay), truncated species characterization, and residual process impurities (residual DNA, residual lipid impurities). Each species needs an acceptance criterion and a rationale for that criterion tied to toxicology or clinical data where available.

3. Build Stability Specifications from Lot Data

If you are preparing an IND and do not yet have three lots of stability data, develop a statistical plan for how specifications will be confirmed as additional lots are manufactured. Reviewers are no longer accepting single-lot derived specifications without a commitment to statistical confirmation — and that commitment needs to appear in your regulatory strategy section.